URGNUroGen Pharma Ltd.

$927M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+26.7% YoY

Gross Profit

$15M86.8% margin

Operating Income

-$22M-128.2% margin

Net Income

-$30M-175.7% margin

EPS (Diluted)

$-1.30

QoQ Revenue Growth

-5.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$113M

Total Liabilities

$230M

Stockholders' Equity

-$117M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$14M	+26.7%
Gross Profit	$15M	$12M	+24.0%
Operating Income	-$22M	-$22M	-0.4%
Net Income	-$30M	-$28M	-6.4%

Revenue Segments

Jelmyto

$17M100%

URGN Q1 2023 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena